Stay updated on Lenvatinib and Pembrolizumab in HCC Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib and Pembrolizumab in HCC Clinical Trial page.

Latest updates to the Lenvatinib and Pembrolizumab in HCC Clinical Trial page
- Check2 days agoChange DetectedThe page's revision label has been updated from v3.5.2 to v3.5.3. This reflects a minor update to the page's metadata or documentation.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedAdded revision note: v3.5.2; removed revision: v3.5.0.SummaryDifference0.0%

- Check24 days agoChange Detected- Padua, Italy, 35128 was replaced by Padova, Italy, 35128 in the locations list.SummaryDifference0.0%

- Check45 days agoChange DetectedAdded the disease term Hepatocellular carcinoma and a Resources section linking to the Genetic and Rare Diseases Information Center. Updated the page revision from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check53 days agoChange DetectedAdded Revision: v3.4.3 and removed Revision: v3.4.2.SummaryDifference0.0%

- Check81 days agoChange DetectedPlain Language Summary added and page updated to Revision 3.4.2 with new dates; funding-status notice removed.SummaryDifference0.3%

Stay in the know with updates to Lenvatinib and Pembrolizumab in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib and Pembrolizumab in HCC Clinical Trial page.